Alvotech

ALVO

Company Profile

  • Business description

    Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

  • Contact

    9, rue de Bitbourg
    LuxembourgL-1273
    LUX

    T: +352 4224500

    https://www.alvotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    1,460

Stocks News & Analysis

stocks

Wide moat stock exchange remains cheap

Aussie stock exchange remains materially undervalued despite growing cost concerns.
stocks

ASX data center player expands pipeline but questions remain

Questions surround Australia’s largest data center developer and its growing pipeline.
stocks

Cheap e-commerce share continues sales momentum

The e-commerce business continues its sales momentum despite challenging backdrop.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,965.0077.800.88%
CAC 408,183.345.53-0.07%
DAX 4025,104.7012.450.05%
Dow JONES (US)51,032.46363.490.72%
FTSE 10010,409.2816.68-0.16%
HKSE25,182.39176.230.70%
NASDAQ26,972.6255.150.20%
Nikkei 22566,329.501,636.382.53%
NZX 50 Index13,244.5538.440.29%
S&P 5007,580.0616.430.22%
S&P/ASX 2008,731.7073.100.84%
SSE Composite Index4,068.5730.07-0.73%

Market Movers